NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Mustang Bio, Inc. MBIO
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.39
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-67.9%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 10-year series below
Revenue
Net income
Per share
USD -0.39
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-67.9%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-14.3%
Each USD of equity lost 68 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 17.6M
total assets, end of FY2025
Total assetsUSD 17.6M
EquityUSD 9.5M
CashUSD 17.3M
Current ratio2.22×
Equity funds 54% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.39
−38.57
−299.95
−10.09
−0.76
−1.14
−1.29
−1.14
−1.24
−1.15
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−67.9
·
−222.4
−97.7
−63.0
−80.0
−105.4
−63.7
−74.4
−125.6
Shares out B
·
·
·
·
·
0.07
0.00
0.00
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed